title: Lymphokine-activated killer cell activity of CD4-CD8- TCR alpha beta + thymocytes.
abstract: Functions of CD4-8-TCR alpha beta+ thymocytes, which are characterized by predominant usage of V beta 8.2 TCR, have remained unclear. In this study, we found that the CD4-8-TCR alpha beta + thymocytes expressed NK1.1 Ag and IL-2R beta-chain but not IL-2R alpha-chain. When the CD4-8- TCR alpha beta + thymocytes were cultured in the presence of IL-2, the CD4-8-TCR alpha beta + thymocytes vigorously proliferated. After 7 days of culture in the presence of 1000 U/ml of IL-2, approximately half of the CD4-8-TCR alpha beta + thymocytes lost NK1.1 Ag. However, the remaining half of the CD4-8-TCR alpha beta + cells showed increasing levels of NK1.1 Ag and acquired killer activity against tumor cells such as YAC-1, P815, and EL-4. These cells also killed syngeneic as well as allogeneic thymocytes. The LAK activity by the NK1.1+ CD4-8-TCR alpha beta + thymocytes was not inhibited by anti-NK1.1, anti-TCR alpha beta, or anti-CD44 mAb but was partially inhibited by anti-LFA-1 mAb. These findings indicate that the CD4-8-TCR alpha beta + thymocyte population can be divided into two population on the basis of NK1.1 expression after culture in the presence of IL-2. The NK1.1 Ag expression on the cultured CD4-8-TCR alpha beta + seems to be correlated to acquisition of LAK activity, although the NK1.1 Ag itself may not be directly involved in the target cell recognition. The present data suggest that the CD4-8- TCR alpha beta + thymocyte population is a functional T cell lineage which may serve as cells of immune defense and/or immune regulation.
authors.affiliation: Institute of Immunological Science, Hokkaido University, Sapporo, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Arase
authors.forename: N
authors.initials: N
authors.lastname: Arase-Fukushi
authors.forename: R A
authors.initials: RA
authors.lastname: Good
authors.forename: K
authors.initials: K
authors.lastname: Onoé
mesh_terms: D000818:Animals; D015704:CD4 Antigens / Q000032:analysis*; D016827:CD8 Antigens / Q000032:analysis*; D002478:Cells, Cultured; D003602:Cytotoxicity, Immunologic; D007376:Interleukin-2 / Q000494:pharmacology; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D008213:Lymphocyte Activation; D051379:Mice; D008810:Mice, Inbred C57BL; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000032:analysis*; D015375:Receptors, Interleukin-2 / Q000032:analysis; D013047:Specific Pathogen-Free Organisms; D013601:T-Lymphocytes / Q000276:immunology*; D014407:Tumor Cells, Cultured
chemical_list: D015704:CD4 Antigens; D016827:CD8 Antigens; D007376:Interleukin-2; D016693:Receptors, Antigen, T-Cell, alpha-beta; D015375:Receptors, Interleukin-2